Sialodacryoadenitis in the rat: effects of immunosuppression on the course of the disease.
Eight-week-old outbred male and female Crl:CD(SD)BR rats were treated with prednisolone (PR) or cyclophosphamide (CY) and were inoculated intranasally with sialodacryoadenitis (SDA) virus. The course of the disease was compared with nonimmunosuppressed, SDA virus-inoculated rats of the same stock. Criteria used to compare SDA in the 3 groups, included histologic changes in salivary and lacrimal glands, immunofluorescent microscopy of paraffin-embedded tissues, serum amylase levels, and antibody response. Based on these criteria, there was little detectable difference in the course and intensity of SDA in PR-treated and nonimmunosuppressed rats. In CY-treated rats, there was a delay in the onset of SDA, in the appearance of inflammatory cells in affected glands, and in the reparative process in the salivary and lacrimal glands. Viral antigen persisted longer in CY-treated rats than in PR-treated and nonimmunosuppressed rats. Antibody to SDA virus was not detected in CY-treated rats. The efficacy of immunosuppression by PR and CY was confirmed by the sheep erythrocyte agglutination procedure performed in selected rats. Male and female rats of the same strain were immunosuppressed beginning 4 weeks after inoculation with SDA virus to produce recrudescence of the disease. Histologic examination of salivary and lacrimal glands, immunofluorescent microscopy, serum amylase values, and viral isolation studies did not reveal evidence of reactivation of a persistent viral infection or viral shedding. Based on these studies, there is no evidence that SDA virus may persist as an inapparent infection after recovery from the disease.
D000681:Amylases / Q000097:blood; D000818:Animals; D003333:Coronaviridae Infections / Q000276:immunology / Q000473:pathology / Q000662:veterinary*; D003520:Cyclophosphamide / Q000009:adverse effects*; D004198:Disease Susceptibility; D005260:Female; D007108:Immune Tolerance / Q000187:drug effects; D007765:Lacrimal Apparatus / Q000473:pathology; D008297:Male; D009297:Nasal Mucosa / Q000382:microbiology; D011239:Prednisolone / Q000009:adverse effects / Q000031:analogs & derivatives*; D051381:Rats / Q000276:immunology; D011919:Rats, Inbred Strains; D012376:Rodent Diseases / Q000276:immunology / Q000473:pathology*; D012401:Rotavirus / Q000302:isolation & purification; D012466:Salivary Gland Diseases / Q000662:veterinary*; D012469:Salivary Glands / Q000473:pathology; D012793:Sialadenitis / Q000276:immunology / Q000473:pathology / Q000662:veterinary*
D003520:Cyclophosphamide; D011239:Prednisolone; D000681:Amylases; C021322:prednisolone hemisuccinate